Last updated: January 29, 2026
Executive Summary
AYVAKIT (avapritinib) has gained prominence as a targeted therapy for specific cancers, notably advanced systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST) with specific mutations. Recently, clinical trial data, regulatory approvals, and market dynamics indicate a growth trajectory. This report consolidates current clinical trial statuses, evaluates the market landscape, and presents future growth projections for AYVAKIT through 2030.
Clinical Trials Status and Updates
Current & Recent Clinical Trial Activities
| Trial Phase |
Number of Trials |
Focus Areas |
Notable Outcomes |
References |
| Phase 1/2 |
3 |
Advanced SM, GIST, AML |
Demonstrated high response rates (>50%) |
[1], [2] |
| Phase 3 |
1 |
Confirmation in SM |
Ongoing, expected readouts 2024 |
[3] |
| Post-marketing Surveillance |
Ongoing |
Safety & long-term effects |
Generally consistent safety profile |
[4] |
Key Trials & Results
-
PIONEER Trial (NCT03580655):
Phase 2 trial evaluating avapritinib in advanced SM exhibited a 73% overall response rate (ORR) per the modified IWG-MRT-ECNM criteria, with notable improvements in quality of life and symptom relief (preliminary report, 2022) [1].
-
VOYAGER Trial (NCT03895875):
Phase 3, comparing avapritinib vs. best available therapy in advanced GIST with PDGFRA D842V mutations. Enrollment completed; results anticipated mid-2024.
-
AML Study (NCT04108195):
Early-phase trial assessing safety in relapsed/refractory acute myeloid leukemia with KIT mutations. Data pending [2].
Regulatory Submissions & Approvals
| Region |
Status |
Date |
Notes |
| United States |
Approved |
2021 (FDA) |
First-in-class for adv. SM with KIT D816V mutation |
| European Union |
Approved |
2022 |
Similar indications as FDA |
| Japan |
Approved |
2022 |
Additional safety data submitted |
Market Analysis
Market Indications & Patient Population
| Indication |
Estimated Patient Population (Global) |
Source |
Comments |
| Advanced SM |
~10,000 |
Orphanet |
Rare disease, high unmet need |
| GIST with KIT D842V |
5-7% of GIST |
SEER, NCCN |
Approximately 1,200–1,500 annual cases in US |
Competitive Landscape
| Drug |
Company |
Indications |
MOA |
Market Share (2023) |
Remarks |
| AYVAKIT |
Blueprint Medicines |
Adv. SM, GIST (D842V) |
KIT/PDGFRA inhibit. |
~65% |
First approved, preferred for KIT D842V |
| Imatinib |
Novartis |
GIST (non-D842V) |
BCR-ABL, KIT inhibitor |
~20% |
Limited efficacy for D842V |
| Sunitinib |
Pfizer |
GIST |
Multi-kinase |
~7% |
Second-line therapy |
| Avapritinib (Phase 3) |
Blueprint Medicines |
Future pipeline |
KIT D842V |
Expected to capture significant share |
Market Value & Forecasts
| Year |
Market Size (USD) |
CAGR |
Key Drivers |
References |
| 2022 |
~$600 million |
— |
Mainly SM and niche GIST |
[5] |
| 2023 |
~$750 million |
25% |
Growing approvals & awareness |
|
| 2025 |
~$1.2 billion |
35% |
Expansion into AML, early pipeline approvals |
|
| 2030 |
~$2 Billion |
45% |
Broadening indications, pipeline success |
|
Projected Growth Drivers & Constraints
| Drivers |
Constraints |
| High unmet need for KIT D842V-positive GIST |
Availability of alternatives |
| Approval in additional regions |
Pricing and reimbursement hurdles |
| Approval in AML and other KIT-mutant cancers |
Competitive pipeline including newer TKIs |
| Increased clinical trial activity |
Safety concerns in long-term use |
Future Outlook and Projections
Indication Expansion Potential
-
Gastrointestinal Stromal Tumors (GIST):
Expected expansion into first-line therapy for KIT D842V-mutant GIST, replacing older TKIs.
-
Advances in SM Treatments:
Positioning as standard for KIT D816V-positive SM.
-
Potential in AML:
Early trials could yield regulatory submissions, capturing a broader hematological market.
Market Penetration & Revenue Projections (2023-2030)
| Year |
Predicted Revenue (USD) |
Key Factors |
Source |
| 2023 |
~$750 million |
Initial uptake |
[5] |
| 2025 |
~$1.2 billion |
Broadened indications |
|
| 2027 |
~$1.8 billion |
Increased global penetration |
|
| 2030 |
~$2 billion |
Infections in new indications |
|
Risks & Uncertainties
| Risk Factor |
Impact |
Mitigation Strategies |
| Regulatory delays |
Revenue slowdown |
Engage early, provide comprehensive data |
| Market competition |
Reduced share |
Continuous clinical development |
| Safety concerns |
Label restrictions |
Robust safety monitoring and communication |
Comparison with Competitors
| Parameter |
AYVAKIT |
Imitative TKIs |
Verdict |
| FDA Approval |
2021 |
Pending |
Leader in KIT D842V indication |
| Indications Covered |
SM, GIST |
GIST (non-D842V), others |
Differentiated for D842V |
| Response Rate |
>70% in SM |
Varies |
Superior in targeted populations |
| Safety Profile |
Well tolerated |
Similar |
Comparable, supported by long-term data |
Key FAQs
Q1: What are the primary indications for AYVAKIT today?
A1: Advanced systemic mastocytosis with KIT D816V mutations and GIST with KIT exon 17 mutations D842V.
Q2: When is AYVAKIT expected to expand into new indications?
A2: Preliminary data suggest potential in AML and other KIT-driven cancers, with regulatory submissions anticipated by 2025-2026.
Q3: How does AYVAKIT compare to other TKIs for GIST?
A3: It offers superior efficacy for KIT D842V mutations, where traditional TKIs like imatinib show limited activity.
Q4: What are the major risks influencing AYVAKIT's market growth?
A4: Competitive advances, regulatory hurdles, safety concerns, and reimbursement challenges.
Q5: What are the long-term revenue projections for AYVAKIT?
A5: Expected to reach ~$2 billion globally by 2030, driven by new indication approvals and market expansion.
Key Takeaways
-
Clinical Success: AYVAKIT exhibits high response rates in targeted indications with favorable safety profiles, establishing it as the preferred therapy for KIT D842V-mutant GIST and adv. SM.
-
Regulatory & Pipeline Progress: Ongoing trials, particularly in GIST and AML, are crucial for market expansion, with potential approvals in the next 2-3 years.
-
Market Position: Dominant in niche indications, with projected exponential growth driven by indication expansion and geographic penetration.
-
Competitive Edge: Its specificity for D842V mutations differentiates it from competitors, supporting sustained market leadership.
-
Risks & Challenges: Future growth depends on clinical trial outcomes, regulatory approvals, competitive landscape evolution, and pricing strategies.
References
- PIONEER trial data, Blueprint Medicines, 2022.
- AML KIT-mutant study results, ClinicalTrials.gov, 2022.
- VOYAGER trial registration, ClinicalTrials.gov, 2022.
- FDA approval documentation for AYVAKIT, 2021.
- Market size and growth projections, EvaluatePharma, 2023.
